Premium
Review seed biopharmaceutical cyclic peptides: From discovery to applications
Author(s) -
Mahatmanto Tunjung
Publication year - 2015
Publication title -
peptide science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.556
H-Index - 125
eISSN - 1097-0282
pISSN - 0006-3525
DOI - 10.1002/bip.22741
Subject(s) - biopharmaceutical , chemistry , cyclic peptide , drug discovery , computational biology , combinatorial chemistry , nanotechnology , biochemical engineering , peptide , biochemistry , microbiology and biotechnology , biology , materials science , engineering
Mini‐proteins (or peptides) with disulfide bond/s and a cyclic backbone offer exciting opportunities for applications in medicine, as these ribosomally synthesized and posttranslationally modified peptides are exceptionally stable and amenable to grafting epitopes with desirable activities. Here I discuss important aspects of the discovery and applications of disulfide‐bonded cyclic peptides from seeds, i.e., the trypsin inhibitor cyclotides and the preproalbumin with sunflower trypsin inhibitor‐derived peptides, focusing on bioanalytical methods for and insights generated from their discovery as well as their potential use as engineering scaffolds for peptide‐based drug design. The recent discovery of their precursors and processing enzymes could potentially enable in planta production of designer disulfide‐bonded cyclic peptides, preferably in edible seeds, and address the demand for new biopharmaceutical peptides in a cost‐effective manner. © 2015 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 104: 804–814, 2015.